Tumor microenvironment activatable immunomodulator for cancer immunotherapy.

Area of Science:

• Oncology
• Immunology
• Biomaterials Science

Background:

• The tumor microenvironment (TME) is a complex ecosystem driving tumor growth, metastasis, and immune evasion.
• It presents significant challenges for effective cancer immunotherapy.
• Understanding TME components is crucial for developing targeted therapies.

Purpose of the Study:

• To review the role of the TME in cancer immunotherapy.
• To highlight the potential of TME-activatable immunomodulators.
• To discuss design principles and applications of these novel agents.

Main Methods:

• Overview of TME characteristics and components influencing tumor progression.
• Summary of TME-activatable immunomodulator design principles and responsive mechanisms (pH, glutathione, enzymes, hypoxia).
• Review of preclinical successes of emerging immunotherapies leveraging TME targeting.

Main Results:

• TME components significantly impact therapeutic resistance and immune evasion.
• TME-activatable immunomodulators demonstrate enhanced tumor penetration and reduced off-target effects.
• Preclinical data support the efficacy of stimuli-responsive immunomodulator delivery.

Conclusions:

• TME-activatable immunomodulators represent a revolutionary approach to cancer immunotherapy.
• Precise control over immunomodulator delivery and activation within the TME is critical.
• Further research is needed to address TME-induced resistance and biosafety concerns.